ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,012.28
-1.46%
Dow Jones
44,713.58
0.65%
US Dollar vs MXN
20.7253
-0.09%
Brent Oil
76.315
0.06%
Bitcoin
101,390.18
-0.66%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) Noticias

MNKD

MannKind (MNKD)

MannKind Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MNKD
FechaHoraFuenteTítuloSímboloCompañía
06/01/202516:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
06/01/202515:30GlobeNewswire Inc.MannKind Expands Executive Leadership TeamNASDAQ:MNKDMannKind Corporation
18/12/202406:00GlobeNewswire Inc.MannKind Corporation Announces Exchange of Convertible Notes for Stock and CashNASDAQ:MNKDMannKind Corporation
16/12/202405:05GlobeNewswire Inc.MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)NASDAQ:MNKDMannKind Corporation
11/12/202405:00GlobeNewswire Inc.CDSCO Approves Afrezza® (insulin human) Inhalation Powder in IndiaNASDAQ:MNKDMannKind Corporation
25/11/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
22/11/202415:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
07/11/202415:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
07/11/202415:02GlobeNewswire Inc.MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateNASDAQ:MNKDMannKind Corporation
05/11/202415:15GlobeNewswire Inc.MannKind to Present at 2024 UBS Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
04/11/202405:05GlobeNewswire Inc.MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
31/10/202415:05GlobeNewswire Inc.MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024NASDAQ:MNKDMannKind Corporation
30/09/202405:00GlobeNewswire Inc.More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)NASDAQ:MNKDMannKind Corporation
18/09/202405:15GlobeNewswire Inc.MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
10/09/202415:30GlobeNewswire Inc.MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
27/08/202415:30GlobeNewswire Inc.MannKind to Present at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
14/08/202407:00GlobeNewswire Inc.Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the BoardNASDAQ:MNKDMannKind Corporation
07/08/202407:00GlobeNewswire Inc.MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
07/08/202404:49IH Market NewsUS Index Futures Rise Amid Earnings Season Optimism, Oil Prices ReboundNASDAQ:MNKDMannKind Corporation
31/07/202405:30GlobeNewswire Inc.MannKind Launches Educational Website to Raise Awareness of NTM Lung DiseaseNASDAQ:MNKDMannKind Corporation
30/07/202415:30GlobeNewswire Inc.MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024NASDAQ:MNKDMannKind Corporation
22/06/202407:00GlobeNewswire Inc.INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
05/06/202405:45GlobeNewswire Inc.Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
29/05/202407:45GlobeNewswire Inc.MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixNASDAQ:MNKDMannKind Corporation
08/05/202415:18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
06/05/202405:05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202415:00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202405:05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202405:05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202405:00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Su Consulta Reciente

LSE
47GT
Morocco 27a
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados